Friday, February 14, 2025

Mpox: Better understanding of tecovirimat resistance

A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic areas in Central and West Africa. Two hundred and fifteen cases of mpox infection were reported to Sant publique France in 2024. Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in an enzyme. Scientists have been studying this resistance, and have been able to describe more precisely how this enzyme interacts with tecovirimat. This research will make it possible to develop novel antiviral therapeutic approaches.

from Top Health News -- ScienceDaily https://ift.tt/9Oe0R24

No comments:

Post a Comment

Natural hormone unlocks a hidden fat burning switch

FGF19 triggers the brain to burn more energy and activate fat-burning cells, offering a potential new path for obesity treatments. The hormo...